Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
168 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H1 2016', provides in depth analysis on Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - The report reviews Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) Overview 10 Therapeutics Development 11 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Stage of Development 11 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Therapy Area 12 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Indication 13 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Products Glance 16 Late Stage Products 16 Early Stage Products 17 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Companies 18 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Universities/Institutes 30 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Therapeutics Assessment 32 Assessment by Monotherapy/Combination Products 32 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 39 AB Science SA 39 Advenchen Laboratories, LLC 41 Amgen Inc. 42 ArQule, Inc. 43 Astellas Pharma Inc. 44 AstraZeneca Plc 45 AVEO Pharmaceuticals, Inc. 46 Bayer AG 47 Boehringer Ingelheim GmbH 48 Bristol-Myers Squibb Company 49 CASI Pharmaceuticals Inc. 50 Celon Pharma Sp. z o.o. 51 Debiopharm International SA 52 Eddingpharm 53 Eisai Co., Ltd. 54 Eli Lilly and Company 56 Evotec AG 57 Hutchison MediPharma Limited 58 Incyte Corporation 59 Johnson & Johnson 60 Les Laboratoires Servier SAS 61 Merck KGaA 62 Novartis AG 63 Principia Biopharma Inc. 65 Vichem Chemie Research Ltd. 66 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Drug Profiles 67 ARQ-087 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 ASP-5878 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 AV-370 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 AZD-4547 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 B-701 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 BAY-1163877 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 BMS-986036 - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 CPL-043 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 Debio-1347 - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 Drugs to Inhibit FGFR3 for Bladder Cancer - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 E-7090 - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 EDP-317 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 ENMD-2076 - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 erdafitinib - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 HMPL-453 - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 INCB-54828 - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 infigratinib - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 lenvatinib mesylate - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 lucitanib - Drug Profile 105 Product Description 105 Mechanism Of Action 105 R&D Progress 105 LY-2874455 - Drug Profile 108 Product Description 108 Mechanism Of Action 108 R&D Progress 108 masitinib - Drug Profile 109 Product Description 109 Mechanism Of Action 109 R&D Progress 109 nintedanib - Drug Profile 123 Product Description 123 Mechanism Of Action 123 R&D Progress 123 pazopanib hydrochloride - Drug Profile 131 Product Description 131 Mechanism Of Action 131 R&D Progress 131 pazopanib hydrochloride + pembrolizumab - Drug Profile 137 Product Description 137 Mechanism Of Action 137 R&D Progress 137 PRN-1371 - Drug Profile 138 Product Description 138 Mechanism Of Action 138 R&D Progress 138 Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile 139 Product Description 139 Mechanism Of Action 139 R&D Progress 139 Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile 140 Product Description 140 Mechanism Of Action 140 R&D Progress 140 S-49076 - Drug Profile 141 Product Description 141 Mechanism Of Action 141 R&D Progress 141 Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile 142 Product Description 142 Mechanism Of Action 142 R&D Progress 142 sprifermin - Drug Profile 143 Product Description 143 Mechanism Of Action 143 R&D Progress 143 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Dormant Projects 145 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Discontinued Products 149 Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Featured News & Press Releases 152 Jun 06, 2016: AB Science announces that Rapporteurs appointed by the EMA have recommended the filing of masitinib in ALS for conditional marketing authorization 152 Jun 06, 2016: Principia Biopharma Announces Presentation of Initial Clinical Data on PRN1371 at 2016 American Society of Clinical Oncology Annual Meeting 152 Jun 01, 2016: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma 153 May 30, 2016: AB Science will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21St Congress of the European Hematology Association 153 May 24, 2016: Eisai To Present on Lenvima at 52nd Annual Meeting of the American Society of Clinical Oncology 154 May 16, 2016: U.S. FDA Approves additional indication for Eisai anti cancer agent LENVIMA in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma 155 May 16, 2016: New Presentations at ATS 2016 Reinforce OFEV (nintedanib) Efficacy, Safety and Tolerability Across Range of Patients with idiopathic pulmonary fibrosis 156 May 12, 2016: CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC) 158 May 09, 2016: LUME-Meso trial enrols first patient: Boehringer Ingelheim's new pivotal study investigating nintedanib for the treatment of malignant pleural mesothelioma 158 May 02, 2016: AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis 159 Apr 20, 2016: Eisai Announces Non-Clinical Research Findings At Aacr 107Th Annual Meeting Regarding Combination Of Anticancer Agent Lenvatinib With Everolimus 160 Apr 15, 2016: Debiopharm International announces presentation at AACR of non-clinical data relating to its targeted investigational compound Debio 1347/CH5183284, a selective FGFR 1,2,3 inhibitor 160 Apr 12, 2016: Highly Anticipated New Treatment Option Now Available for Canadians with Select Type of Thyroid Cancer 161 Apr 11, 2016: Masitinib in Amyotrophic Lateral Sclerosis (ALS) 162 Apr 06, 2016: AB Science Will Host Live Webcast On Phase 3 Interim Analysis In ALS On 8 April 2016, 165 Appendix 167 Methodology 167 Coverage 167 Secondary Research 167 Primary Research 167 Expert Panel Validation 167 Contact Us 167 Disclaimer 168
List of Tables
Number of Products under Development for, H1 2016 11 Number of Products under Development by Therapy Area, H1 2016 12 Number of Products under Development by Indication, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Early Stage Products, H1 2016 17 Number of Products under Development by Companies, H1 2016 18 Number of Products under Development by Companies, H1 2016 (Contd..1) 19 Products under Development by Companies, H1 2016 20 Products under Development by Companies, H1 2016 (Contd..1) 21 Products under Development by Companies, H1 2016 (Contd..2) 22 Products under Development by Companies, H1 2016 (Contd..3) 23 Products under Development by Companies, H1 2016 (Contd..4) 24 Products under Development by Companies, H1 2016 (Contd..5) 25 Products under Development by Companies, H1 2016 (Contd..6) 26 Products under Development by Companies, H1 2016 (Contd..7) 27 Products under Development by Companies, H1 2016 (Contd..8) 28 Products under Development by Companies, H1 2016 (Contd..9) 29 Number of Products under Investigation by Universities/Institutes, H1 2016 30 Products under Investigation by Universities/Institutes, H1 2016 31 Assessment by Monotherapy/Combination Products, H1 2016 32 Number of Products by Stage and Mechanism of Action, H1 2016 34 Number of Products by Stage and Route of Administration, H1 2016 36 Number of Products by Stage and Molecule Type, H1 2016 38 Pipeline by AB Science SA, H1 2016 39 Pipeline by Advenchen Laboratories, LLC, H1 2016 41 Pipeline by Amgen Inc., H1 2016 42 Pipeline by ArQule, Inc., H1 2016 43 Pipeline by Astellas Pharma Inc., H1 2016 44 Pipeline by AstraZeneca Plc, H1 2016 45 Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 46 Pipeline by Bayer AG, H1 2016 47 Pipeline by Boehringer Ingelheim GmbH, H1 2016 48 Pipeline by Bristol-Myers Squibb Company, H1 2016 49 Pipeline by CASI Pharmaceuticals Inc., H1 2016 50 Pipeline by Celon Pharma Sp. z o.o., H1 2016 51 Pipeline by Debiopharm International SA, H1 2016 52 Pipeline by Eddingpharm, H1 2016 53 Pipeline by Eisai Co., Ltd., H1 2016 54 Pipeline by Eli Lilly and Company, H1 2016 56 Pipeline by Evotec AG, H1 2016 57 Pipeline by Hutchison MediPharma Limited, H1 2016 58 Pipeline by Incyte Corporation, H1 2016 59 Pipeline by Johnson & Johnson, H1 2016 60 Pipeline by Les Laboratoires Servier SAS, H1 2016 61 Pipeline by Merck KGaA, H1 2016 62 Pipeline by Novartis AG, H1 2016 63 Pipeline by Principia Biopharma Inc., H1 2016 65 Pipeline by Vichem Chemie Research Ltd., H1 2016 66 Dormant Projects, H1 2016 145 Dormant Projects (Contd..1), H1 2016 146 Dormant Projects (Contd..2), H1 2016 147 Dormant Projects (Contd..3), H1 2016 148 Discontinued Products, H1 2016 149 Discontinued Products (Contd..1), H1 2016 150 Discontinued Products (Contd..2), H1 2016 151
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
